• Muhammet Gülhan, Uğur Önal, Neşe Demirci, Gulcan Cetin, Abdullah Calisir, Damla Köksalan, Kübra Solmaz, Ayhan Kars, Cetin Kilinc, and Sedat Gülten.
• Kastamonu Training and Research Hospital, Department of Infectious Diseases - Kastamonu, Turkey.
• Rev Assoc Med Bras (1992). 2022 Mar 1; 68 (3): 318322318-322.

ObjectiveIn coronavirus disease 2019, a rapidly progressive inflammatory process is considered to be the main cause of organ damage and mortality. Therefore, the importance of anti-inflammatory treatments such as tocilizumab is increasing.MethodsA total of 107 patients who received tocilizumab between March 2020 and March 2021 were included in the study. The primary termination point was mortality. We compared surviving and deceased patients by the stage of the disease and where the drug was given (service or intensive care unit).ResultsThe mean age was 60.8±14.6 years (minimum 29 years, maximum 96 years). According to the WHO staging system, 16 (15%) patients had moderate, 47 (43.9%) patients had severe, 44 (41.1%) patients had a critical illness. Although all patients were admitted to the service, 26 (24.3%) patients received tocilizumab in the intensive care unit. Of 107 patients, 80 (74.7%) survived and 27 (25.2%) died. Mortality was found to be significantly higher in critical patients (96.3%), severe patients (3.7%), and moderate patients (0%) (p<0.001). Peripheral oxygen saturation measured at admission was found to be significantly lower in patients who died. The initial saturations (p=0.008) were found to have independent effects on mortality.ConclusionThe results showed that tocilizumab is an effective treatment option for coronavirus disease 2019 disease and reduces mortality, but the key point is timing.

10 keywords...

hide…